At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 1 Randomized Study of MEDI-551 in Subjects With Relapsing Forms of Multiple Sclerosis
In Brief
A Phase 1 clinical trial evaluating MEDI-551 30 MG-IV, MEDI-551 60 MG-SC, and 4 other interventions for Multiple Sclerosis, Relapsing Forms. Completed, enrolled 56 participants across 16 sites in 4 countries.
Detailed Summary
The purpose of this study is to evaluate the safety and tolerability of ascending intravenous (IV) and subcutaneous (SC) doses of MEDI-551 in adult subjects with relapsing forms of multiple sclerosis (MS).
Study Details
Timeline
Interventions
Participants received a fixed IV dose of 30 milligram (mg) MEDI-551 infused on Days 1 and 15.
Participants received SC injection of 60 mg MEDI-551 on Day 1.
Participants received either a fixed IV dose of placebo matching with MEDI- 551 on Days 1 and 15 or SC injection on Day 1
Participants received a fixed IV dose of 100 mg MEDI-551 infused on Days 1 and 15.
Participants received SC injection of 300 mg MEDI-551 on Day 1.
Participants received a fixed IV dose of 600 mg MEDI-551 infused on Days 1 and 15.